Check out Frontage's CBO, Hugh Davis, PhD, interview with Contract Pharma about Frontage's range of services and its expansion into biologics and early development capabilities.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
In this podcast, Hugh Davis, Chief Business Officer at Frontage Laboratories, discusses how bioanalytical laboratories like Frontage keep up with the latest therapies, challenges of a clinical development program design, bioanalytical considerations in developing assays, and the future of this field in the next 5-10 years.
Frontage has developed a next-generation sequencing (NGS)-based method to rapidly determine the genotype of 300+ genes involved in ADME, called the Frontage PGx NGS Test.
In this white paper, we show testing of two critical parameters for the method validation of Gyrolab: 1) carryover contamination and 2) after MRD (minimum required dilution) stability.